Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

MicroRNA --a compelling target for anti-HCV therapy

Sep. 27, 2005

HCV RNA polymerase inhibitors claimed in Japan Tobacco patent

Sep. 27, 2005

XTLbio licenses anti-HCV compounds and technology from VivoQuest

Sep. 26, 2005

GSK's Zefix approved in Japan for HBV-associated cirrhosis

Sep. 26, 2005

Xoma signs manufacture agreement for Cubist's HepeX-B biologic

Sep. 26, 2005

Remicade now approved in U.S. for ulcerative colitis

Sep. 20, 2005

Novel NS5B polymerase inhibitor with in vitro efficacy and in vivo bioavailability

Sep. 20, 2005

KOS-2187: Novel motilide chosen as a clinical candidate

Sep. 20, 2005

Phase II data on the benefits of once-daily SPD-476 in ulcerative colitis

Sep. 19, 2005

Private financing to support preclinical development of Riotech's IFN-alpha-8

Sep. 16, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...